Drugs sold sans regulator’s nod, safety studies

In a shocking case which has come to light of the Union health ministry, domestic companies have been manufacturing and marketing ‘harmful’ medicines, without conducting studies to establish their safety and efficacy, and without approval of the national drug regulator. To make matters worse, some of these drugs are not even approved globally, but are being manufactured in India, putting patients at risk.

In the most recent matter unearthed after multiple raids were conducted on April 3 in Daman, Indore, Bengaluru and Mumbai, Central Drugs Standard Control Organisation has decided to prosecute a littleknown manufacturer Olive Health Care, while companies including Alkem, Intas Pharma, Koye Pharmaceuticals, Macleods Pharma, Pharmanova Speciality and Accumentis Healthcare, are being directed to recall these ‘dangerous’ medicines from the market.

Drugs sold sans regulator’s nod, safety studies
The most serious violation is in the case of Enclomiphene, used for testosterone deficiency, which is not approved by any regulator in the world. Others under scrutiny include Dienogest (used for pelvic pain) and Ulipristal (used to treat uterine fibroids), being manufactured without approval since 2015, official sources told TOI, adding this was only a tip of the iceberg.

Major companies are using loopholes in the Drugs and Cosmetic Act by engaging little-known firms for manufacturing these unapproved and harmful medicines, experts say.

  • Related Posts

    NHS to lose out on new drugs, pharma firm warns

    NHS patients will lose access to new cutting-edge treatments because of skyrocketing costs, the pharmaceutical giant Novartis has claimed amid a row over drug pricing deals. The warning comes after…

    Trump’s tariffs on India: What forced the US govt to leave Indian pharma out of the 50% tax bracket?

    The Indian pharmaceutical industry has been exempted from immediate tariff increases in the US due to the significance of generic medications for providing affordable healthcare in the country. This decision…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    NHS to lose out on new drugs, pharma firm warns

    NHS to lose out on new drugs, pharma firm warns

    Trump’s tariffs on India: What forced the US govt to leave Indian pharma out of the 50% tax bracket?

    Trump’s tariffs on India: What forced the US govt to leave Indian pharma out of the 50% tax bracket?

    Fake medicines worth Rs 2.13 crore recovered from Himanshu Agarwal’s warehouse, case registered

    Fake medicines worth Rs 2.13 crore recovered from Himanshu Agarwal’s warehouse, case registered

    UNESCO Chair on Global Health backs PM Modi’s Call on Obesity

    UNESCO Chair on Global Health backs PM Modi’s Call on Obesity